175 related articles for article (PubMed ID: 29250809)
21. The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2.
Beke L; Nuytten M; Van Eynde A; Beullens M; Bollen M
Oncogene; 2007 Jul; 26(31):4590-5. PubMed ID: 17237810
[TBL] [Abstract][Full Text] [Related]
22. Extracellular Vesicles from Metastatic Rat Prostate Tumors Prime the Normal Prostate Tissue to Facilitate Tumor Growth.
Halin Bergström S; Hägglöf C; Thysell E; Bergh A; Wikström P; Lundholm M
Sci Rep; 2016 Aug; 6():31805. PubMed ID: 27550147
[TBL] [Abstract][Full Text] [Related]
23. Chemokine (C-X-C motif) ligand 1 (CXCL1) protein expression is increased in high-grade prostate cancer.
Miyake M; Lawton A; Goodison S; Urquidi V; Rosser CJ
Pathol Res Pract; 2014 Feb; 210(2):74-8. PubMed ID: 24252309
[TBL] [Abstract][Full Text] [Related]
24. Structural and molecular biology of PSP94: Its significance in prostate pathophysiology.
Anklesaria JH; Mhatre DR; Mahale SD
Front Biosci (Landmark Ed); 2018 Jan; 23(3):535-562. PubMed ID: 28930560
[TBL] [Abstract][Full Text] [Related]
25. Differential expression of neuropilin-1 in malignant and benign prostatic stromal tissue.
Vanveldhuizen PJ; Zulfiqar M; Banerjee S; Cherian R; Saxena NK; Rabe A; Thrasher JB; Banerjee SK
Oncol Rep; 2003; 10(5):1067-71. PubMed ID: 12883660
[TBL] [Abstract][Full Text] [Related]
26. Asporin is a stromally expressed marker associated with prostate cancer progression.
Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
[TBL] [Abstract][Full Text] [Related]
27. Alterations in LMTK2, MSMB and HNF1B gene expression are associated with the development of prostate cancer.
Harries LW; Perry JR; McCullagh P; Crundwell M
BMC Cancer; 2010 Jun; 10():315. PubMed ID: 20569440
[TBL] [Abstract][Full Text] [Related]
28. Promoter variants in the MSMB gene associated with prostate cancer regulate MSMB/NCOA4 fusion transcripts.
Lou H; Li H; Yeager M; Im K; Gold B; Schneider TD; Fraumeni JF; Chanock SJ; Anderson SK; Dean M
Hum Genet; 2012 Sep; 131(9):1453-1466. PubMed ID: 22661295
[TBL] [Abstract][Full Text] [Related]
29. SIGIRR/TIR8, an important regulator of TLR4 and IL-1R-mediated NF-κB activation, predicts biochemical recurrence after prostatectomy in low-grade prostate carcinomas.
Bauman TM; Becka AJ; Sehgal PD; Huang W; Ricke WA
Hum Pathol; 2015 Nov; 46(11):1744-51. PubMed ID: 26344417
[TBL] [Abstract][Full Text] [Related]
30. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
31. Association of transcript levels of 10 established or candidate-biomarker gene targets with cancerous versus non-cancerous prostate tissue from radical prostatectomy specimens.
Väänänen RM; Lilja H; Cronin A; Kauko L; Rissanen M; Kauko O; Kekki H; Vidbäck S; Nurmi M; Alanen K; Pettersson K
Clin Biochem; 2013 May; 46(7-8):670-4. PubMed ID: 23391636
[TBL] [Abstract][Full Text] [Related]
32. A subset of high Gleason grade prostate carcinomas contain a large burden of prostate cancer syndecan-1 positive stromal cells.
Sharpe B; Alghezi DA; Cattermole C; Beresford M; Bowen R; Mitchard J; Chalmers AD
Prostate; 2017 May; 77(13):1312-1324. PubMed ID: 28744948
[TBL] [Abstract][Full Text] [Related]
33. Cysteine-rich secretory protein 3 and β-microseminoprotein on prostate cancer needle biopsies do not have predictive value for subsequent prostatectomy outcome.
Hoogland AM; Dahlman A; Vissers KJ; Wolters T; Schröder FH; Roobol MJ; Bjartell AS; van Leenders GJ
BJU Int; 2011 Oct; 108(8):1356-62. PubMed ID: 21410630
[TBL] [Abstract][Full Text] [Related]
34. Activation of mammalian target of rapamycin signaling pathway markers in minute adenocarcinoma of the prostate.
Faraj SF; Albadine R; Chaux A; Gonzalez-Roibon N; Hicks J; Humphreys E; Partin A; Netto GJ
Urology; 2013 Nov; 82(5):1083-9. PubMed ID: 24035134
[TBL] [Abstract][Full Text] [Related]
35. Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia.
Jack GS; Brash AR; Olson SJ; Manning S; Coffey CS; Smith JA; Shappell SB
Hum Pathol; 2000 Sep; 31(9):1146-54. PubMed ID: 11014584
[TBL] [Abstract][Full Text] [Related]
36. PBOV1 as a potential biomarker for more advanced prostate cancer based on protein and digital histomorphometric analysis.
Carleton NM; Zhu G; Gorbounov M; Miller MC; Pienta KJ; Resar LMS; Veltri RW
Prostate; 2018 May; 78(7):547-559. PubMed ID: 29520928
[TBL] [Abstract][Full Text] [Related]
37. High miR-205 expression in normal epithelium is associated with biochemical failure - an argument for epithelial crosstalk in prostate cancer?
Nordby Y; Richardsen E; Ness N; Donnem T; Patel HRH; Busund LT; Bremnes RM; Andersen S
Sci Rep; 2017 Nov; 7(1):16308. PubMed ID: 29176717
[TBL] [Abstract][Full Text] [Related]
38. Cellular expression of beta-microseminoprotein (beta-MSP) mRNA and its protein in untreated prostate cancer.
Tsurusaki T; Koji T; Sakai H; Kanetake H; Nakane PK; Saito Y
Prostate; 1998 May; 35(2):109-16. PubMed ID: 9568674
[TBL] [Abstract][Full Text] [Related]
39. Nedd4L expression is downregulated in prostate cancer compared to benign prostatic hyperplasia.
Hu XY; Xu YM; Fu Q; Yu JJ; Huang J
Eur J Surg Oncol; 2009 May; 35(5):527-31. PubMed ID: 19004604
[TBL] [Abstract][Full Text] [Related]
40. Expression of Peroxisome Proliferator Activated Receptor gamma in Prostatic Adenocarcinoma.
Park HK; Kim H; Kim HG; Cho YM; Jung WY; Han HS; Hwang TS; Kwon GY; Lim SD
J Korean Med Sci; 2015 May; 30(5):533-41. PubMed ID: 25931782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
